For citation purposes: Pokharel P, Bella JN. Regression of left ventricular hypertrophy: Lessons from clinical trials. OA Evidence-Based Medicine 2013 Nov 30;1(2):13.

Review

 
Systematic Reviews

Regression of left ventricular hypertrophy: lessons from clinical trials

P Pokharel, JN Bella,
 

Authors affiliations

(1) Department of Medicine, Division of Cardiology, Bronx-Lebanon Hospital Center, New York, NY 10457, USA

(2) Albert Einstein College of Medicine, Bronx, NY 10461, USA

* Corresponding author Email: jonnbella@earthlink.net

Abstract

Introduction

Hypertension is an epidemic that affects more than 1 billion people worldwide annually. Left ventricular hypertrophy is the phenotypic expression of hypertensive heart disease, which depends on complex interactions among genetic makeup, environmental factors and lifestyle. Left ventricular hypertrophy has been shown to be independently associated with adverse cardiovascular morbidity and mortality. Targeting left ventricular hypertrophy with different pharmacological agents and lifestyle modifications has been associated with favourable results and results in improved outcome. Evidence shows that the drug targets rennin–angiotensin–aldosterone are more effective system in reducing left ventricular mass. Moving forward, the new frontier in this field will be to understand the genetic influences on left ventricular hypertrophy regression and progression and ways to intervene early and treat this public health burden.

Conclusion

Targeting left ventricular hypertrophy regression with various antihypertensive agents results in improved clinical outcomes. Therefore regression of LVH can be considered surrogate endpoint in the treatment of hypertensive heart disease

Licensee OA Publishing London 2013. Creative Commons Attribution License (CC-BY)
Keywords